Oncology Drug Reference Sheet: Amivantamab-Vmjw

Aileen Anglin APRN, ACNP-BC, AOCNP®


After clinical trials demonstrated a 40% overall response rate with 63% of responses lasting six months or more, on May 21, 2021, the U.S. Food and Drug Administration (FDA) approved amivantamab-vmjw (RybrevantTM) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion variants, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

View Article @ voice.ons.org

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles

Related Topics